GlobalRPh RX List - CARAFATE suspension
- Product / population
- CARAFATE oral suspension; aluminum-related renal safety, not a renal dose-reduction table.
- Renal measure
- Qualitative chronic renal failure/dialysis precaution
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Selected sections only; not a complete prescribing monograph or independent clinician approval.
The hosted label mirror is not independent corroboration of its underlying label. Official-label confirmation of this new card remains pending unless a separate official card is shown.
Renal dosing, restrictions and evidence limits
Small amounts of aluminum are absorbed during treatment. Chronic renal failure and dialysis impair elimination of absorbed aluminum; accumulation can cause osteomalacia, osteodystrophy or encephalopathy. Protein-bound circulating aluminum is not removed by dialysis.
Use cautiously in chronic renal failure and consider concurrent aluminum-containing products. Limited gastrointestinal absorption does not establish safety in advanced CKD. The selected paragraph supplies neither a quantitative renal reduction nor a dialysis replacement schedule.
Source: https://globalrph.com/rx-list/carafate-suspension-drug/